Metil 5-aminolevulinate

Phase 2Small molecule

IInstituto Nacional de Cancer, Brazil

Metil 5-aminolevulinate is one of 7 small molecule programs targeting Cheilitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CheilitisActive, not recruiting

CheilitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Cheilitis

#DrugCompanyPhaseTrials

Aldara

BBausch Health Americas, Inc.

Approved

—2

Aminolevulinic Acid Hydrochloride

MMayo Clinic

Approved

1 3

Ingenol Metabute

LEO Pharma

Phase 2

1 4

Metil 5-aminolevulinate

IInstituto Nacional de Cancer, Brazil

Phase 2

1 5

Dexpanthenol

Bayer

Phase 1

1 6

Er:yag AFL-PDT

DDong-A University

Phase 1

1 7

MAL-PDT

DDong-A University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cheilitis1 trial

Photodynamic Therapy With Metil 5-aminolevulinate for Actinic Cheilitis - Phase 2 Clinical Trial

Unknown status·IInstituto Nacional de Cancer, Brazil·Phase 2·NCT03990636·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Metil 5-aminolevulinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metil 5-aminolevulinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metil 5-aminolevulinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto Nacional de Cancer, Brazil company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstituto Nacional de Cancer, Brazil

Metil 5-aminolevulinate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cheilitis1 trial

References

Drug Info

Quick Facts

Related News